Drug Profile
IMNN 001
Alternative Names: DNA-based immunotherapy - Imunon; EGEN-001; GEN-1; IL-12 gene therapy - EGEN; IL-12 gene therapy - Expression Genetics; IL-12 gene therapy - Imunon; IMNN-001; Interleukin-12 gene therapy - EGEN; Interleukin-12 gene therapy - Expression Genetics; Interleukin-12 gene therapy - Imunon; phIL-12-005/PPCLatest Information Update: 20 Nov 2023
Price :
$50
*
At a glance
- Originator Expression Genetics
- Developer Gynecologic Oncology Group; Imunon
- Class Antineoplastics; Cytokine genes; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference; Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- No development reported Colorectal cancer
- Discontinued Glioblastoma
Most Recent Events
- 14 Nov 2023 IMUNON plans to submit an Investigational New Drug (IND) application for Phase I/II trial in the first quarter of 2024 in USA
- 14 Nov 2023 Efficacy and safety data from the phase I/II OVATION 2 trial in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer released by IMUNON
- 28 Sep 2023 Interim efficacy data from the phase I/II OVATION 2 trial in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer released by IMUNON